A tiny pharmacy is identifying big problems with common drugs, including Zantac Print
Written by FHI's Week in Review   
Monday, 11 November 2019 18:19

Carolyn Y. Johnson, Science Reporter for the Washington Post delivers this interesting story on November 8, 2019.

NEW HAVEN, Conn. - The escalating global recall of Zantac, the heartburn pill that once ranked as the world's best-selling drug, has its roots not in government oversight or a high-profile lawsuit, but in a tiny online pharmacy here whose founders feared that U.S. drugs might not be as safe as people think. The pharmacy, Valisure, is a start-up with only 14 full-time employees. But since its scientists alerted American regulators that Zantac and its generic form, ranitidine, contained a chemical thought to cause cancer, more than 40 countries from Australia to Vietnam have either stopped sales, launched investigations or otherwise stepped in to protect consumers from possible health risks. In the United States, the Food and Drug Administration this month confirmed unacceptable levels of the chemical, N-nitrosodimethylamine (NDMA), in some ranitidine products.

Read more in the current issue of Week in Review>>

Last Updated on Monday, 11 November 2019 18:26